Clinical results obtained by immunotherapy in dogs

Changes in the biological responseAdministration routeType of tumor diseaseUsed in association withResults
Calmette-Guérin bacillus (CGB)IntravenousOsteosarcomaAmputationSurvival
IntravenousMammary tumorsSurgerySurvival
CGB and Corynebacterium parvum (CP)IntratumoralMammary tumorsSurgeryInefficient
Corynebacterium parvum (CP)IntratumoralMammary tumorsSurgeryInefficient
IntravenousOral cavity melanomaSurgery and/or cryosurgeryLittle efficient
LevamisoleOralMammary tumorsSurgeryInefficient
OralLymphomaChemotherapyInefficient
OralNasal cavity cancerSurgerySurvival
Muranyl tripeptide phosphatidyl- ethanolamine (MTPPE)IntravenousOsteosarcomaAmputation and chemotherapy (cisplatin)Survival
Staphylococcus aureus Cowan I (SAC)PlasmapheresisMammary tumor-Tumor necrosis
Mixed bacterial vaccine (MBV) (Serratia marcescins and Streptococcus pyogenes)IntramuscularOral cavity melanomaSurgery or cryosurgeryInefficient
IntramuscularLymphomaChemotherapyRemission, survival, unchanged
Monoclonal antibodies mouse-derived canine antilymphomaIntravenousLymphomaChemotherapy until clinical remission is obtained, then maintenance of remission with monoclonal antibodiesRemission, survival
Calmette-Guérin bacillus (CGB)IntravenousOsteosarcomaAmputationSurvival
IntravenousMammary tumorsSurgerySurvival
CGB and Corynebacterium parvum (CP)IntratumoralMammary tumorsSurgeryInefficient
Corynebacterium parvum (CP)IntratumoralMammary tumorsSurgeryInefficient
IntravenousOral cavity melanomaSurgery and/or cryosurgeryLittle efficient
LevamisoleOralMammary tumorsSurgeryInefficient
OralLymphomaChemotherapyInefficient
OralNasal cavity cancerSurgerySurvival
Muranyl tripeptide phosphatidyl- ethanolamine (MTPPE)IntravenousOsteosarcomaAmputation and chemotherapy (cisplatin)Survival
Staphylococcus aureus Cowan I (SAC)PlasmapheresisMammary tumor-Tumor necrosis
Mixed bacterial vaccine (MBV) (Serratia marcescins and Streptococcus pyogenes)IntramuscularOral cavity melanomaSurgery or cryosurgeryInefficient
IntramuscularLymphomaChemotherapyRemission, survival, unchanged
Monoclonal antibodies mouse-derived canine antilymphomaIntravenousLymphomaChemotherapy until clinical remission is obtained, then maintenance of remission with monoclonal antibodiesRemission, survival
Tumor cell vaccines5 vaccines in 7 weeks (administration route not mentioned)LymphomaChemotherapy, in animals in remission, injection of irradiated tumor cellsRemission, survival, unchanged
IntralymphaticLymphomaChemotherapy in order to obtain remission + whole body radiationRemission, survival, unchanged
Bone marrow graftIntravenousLymphomaChemotherapy in order to obtain remission + whole body radiation25% of dogs with long survival
Blood component therapyIntravenous, total blood or blood plasma transfusionLymphoma and/or leukemia-Complete remission: 4 cases; regression > 50%: 8 cases. No regression: 4 cases, but transient efficacy

From: Chapter 19, PRINCIPLES OF ANTICANCER THERAPY

Cover of Comparative Oncology
Comparative Oncology.
Baba AI, Câtoi C.
Copyright © 2007, The Publishing House of the Romanian Academy.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.